Table of Contents

company-logo

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and provision of related services in the United States, Canada, Europe, Australia, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its contract research organization services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.

ImmunoPrecise Antibodies Dividend Announcement

• ImmunoPrecise Antibodies does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on ImmunoPrecise Antibodies dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

ImmunoPrecise Antibodies Dividend History

ImmunoPrecise Antibodies Dividend Yield

ImmunoPrecise Antibodies current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing ImmunoPrecise Antibodies stock? Use our calculator to estimate your expected dividend yield:

ImmunoPrecise Antibodies Financial Ratios

P/E ratio-0.58
PEG ratio0.00
P/B ratio0.49
ROE-65.48%
Payout ratio0.00%
Current ratio0.99
Quick ratio0.82
Cash Ratio0.35

ImmunoPrecise Antibodies Dividend FAQ

Does ImmunoPrecise Antibodies stock pay dividends?
ImmunoPrecise Antibodies does not currently pay dividends to its shareholders.
Has ImmunoPrecise Antibodies ever paid a dividend?
No, ImmunoPrecise Antibodies has no a history of paying dividends to its shareholders. ImmunoPrecise Antibodies is not known for its dividend payments.
Why doesn't ImmunoPrecise Antibodies pay dividends?
There are several potential reasons why ImmunoPrecise Antibodies would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will ImmunoPrecise Antibodies ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While ImmunoPrecise Antibodies has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is ImmunoPrecise Antibodies a dividend aristocrat?
ImmunoPrecise Antibodies is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is ImmunoPrecise Antibodies a dividend king?
ImmunoPrecise Antibodies is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is ImmunoPrecise Antibodies a dividend stock?
No, ImmunoPrecise Antibodies is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy ImmunoPrecise Antibodies stocks?
To buy ImmunoPrecise Antibodies you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy ImmunoPrecise Antibodies stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.